4th November, 2026

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001
Scrip Code: 533573

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: APLLTD

Dear Sir/Madam,

Sub: Press Release on the Unaudited Financial Results for the quarter and half year ended 30th September, 2026.

With reference to the captioned subject, please find enclosed herewith the Press Release on the Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2026.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited
CHIRAG K SHUKLA
Digitally signed by CHIRAG K SHUKLA
Date: 2026.11.04 14:32:20 +05'30'
Chirag K. Shukla
Company Secretary

Encl.: A/a.

Press Release

Alembic Pharmaceuticals reports strong Q2 FY27 performance

Revenue up 36%; PAT up 81% YoY

Vadodara, November 4th, 2026: Alembic Pharmaceuticals Limited reported its consolidated financial results for the second quarter and half year ended 30th September, 2026.

Financial Highlights for Q2 FY27

- Revenue from operations increased by 36% YoY to Rs.2603 Cr.
- EBITDA up by 78% YoY to Rs. 578 Cr, margin at 22%
- Profit After Tax at Rs. 335 Cr, up 81% YoY

Commenting on the results, Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited, said,

"We delivered another quarter of strong, broad-based growth and improved profitability, reflecting consistent execution across markets. Our US business delivered an exceptional performance, driven by strong volume growth and new launches, while India regained momentum as Ex-US and API continued their growth trajectories. In India Branded, improving momentum in chronic therapies is strengthening the quality of growth, while in US Branded, we are encouraged by the traction building across our existing portfolio. Following a strong first half, we are well positioned to sustain growth and create long-term value for all our stakeholders"

Operational Highlights

India Branded Business

- India Branded Business delivered 14% YoY growth, reaching Rs 725 Cr. in revenue for the quarter.
- Gynecology, Cardiology, Gastrology and Ophthalmology registered robust growth.
- Animal Health continued its growth momentum with 23% growth for the quarter.

International Business

- US Formulations grew by 77% to Rs. 1003 Cr.
- 3 Launches in the US market during the quarter.
- Ex-US grew by 12% to Rs. 440 Cr.
- 1 ANDA approval received during the quarter, 245 cumulative ANDA approvals.

API Business

- API business grew by 39% to Rs. 436 Cr.

The summary of Revenue from Operations is as under:

(Rs in Cr.)

Particulars	Q2 FY26	Q2 FY27	% Change	H-1 FY 26	H-1 FY 27	% Change
Formulations						
India	639	725	14%	1238	1367	10%
USA	566	1003	77%	1089	1781	64%
Ex- US	392	440	12%	719	823	14%
API	314	436	39%	575	782	36%
Total	**1910**	**2603**	**36%**	**3621**	**4753**	**31%**

Earnings Call: Alembic Pharmaceuticals Limited will host an investor call at 5.00 pm IST on November 04, 2026, where the senior management will discuss the Company's performance and answer questions from participants. Please dial the numbers provided below ten minutes ahead of the scheduled start time to participate in this conference call. The dial-in number for this call is +91 22 6280 1411/ +91 22 7115 8312. Other toll numbers are listed in the conference call invitation, which is posted on the Company website www.alembicpharmaceuticals.com. The operator will provide instructions on asking questions before the start of the call.

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India.
Information about the company can be found at www.alembicpharmaceuticals.com; (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information, contact:

Isha Lamba: Phone: +91 022- 66951652 Email: isha.lamba@alembic.co.in